Literature DB >> 29305671

Investigation Into the Effects of Tenilsetam on Markers of Neuroinflammation in GFAP-IL6 Mice.

Erika Gyengesi1,2, Huazheng Liang3,4, Christopher Millington1, Sandra Sonego1, Daniel Sirijovski5, Dhanushka Gunawardena1, Karthik Dhananjayan1, Madhuri Venigalla1, Garry Niedermayer5, Gerald Münch1,2,6.   

Abstract

PURPOSE: To test the short- and long-term effects of Tenilsetam on chronic neuroinflammation in the GFAP-IL6 mouse.
METHODS: From 3 months of age, GFAP-IL6 mice were divided into 2 groups and fed with Tenilsetam enriched food pellets or control food pellets, respectively, for either 5 or 15 months. Total numbers of Iba-1+ microglia, TSPO+ cells were determined using an unbiased stereological method. Levels of methylglyoxal and TNF-α in the cerebellar homogenate were tested using HPLC and ELISA, respectively.
RESULTS: Tenilsetam decreased the total number of Iba-1+ microglia in both the cerebellum and the hippocampus of GFAP-IL6 mice at 8 months and in the cerebellum at 18 months. In the cerebellum, it decreased the density of microglia in GFAP-IL6 mice to a similar level after 5 and 15 months' feeding. Tenilsetam prevented the volume loss of the cerebellum at 8 months. It also significantly decreased TNF-α in the cerebellum of GFAP-IL6 mice to a similar level of WT mice after 15 months of feeding.
CONCLUSION: Tenilsetam has anti-inflammatory effects evidenced by the decreased number of microglia in both the cerebellum and hippocampus, and decreased TNF-α levels in the GFAP-IL6 Tenilsetam fed animals.

Entities:  

Keywords:  alzheimer’s disease; anti-inflammatory drug; glycation; methylglyoxal; microglia; tumour necrosis factor-α

Mesh:

Substances:

Year:  2018        PMID: 29305671     DOI: 10.1007/s11095-017-2326-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  59 in total

1.  Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment.

Authors:  J Priller; A Flügel; T Wehner; M Boentert; C A Haas; M Prinz; F Fernández-Klett; K Prass; I Bechmann; B A de Boer; M Frotscher; G W Kreutzberg; D A Persons; U Dirnagl
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

Review 2.  Alzheimer's disease: inside, outside, upside down.

Authors:  S D Yan; A M Schmidt; D Stern
Journal:  Biochem Soc Symp       Date:  2001

Review 3.  Activated astrocytes: a therapeutic target in Alzheimer's disease?

Authors:  Stacey Fuller; Gerald Münch; Megan Steele
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

4.  The carbonyl scavengers aminoguanidine and tenilsetam protect against the neurotoxic effects of methylglyoxal.

Authors:  Julie Webster; Christin Urban; Katrin Berbaum; Claudia Loske; Alan Alpar; Ulrich Gärtner; Susana Garcia de Arriba; Thomas Arendt; Gerald Münch
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

5.  Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration.

Authors:  Solomon S Shaftel; Thaddeus J Carlson; John A Olschowka; Stephanos Kyrkanides; Sarah B Matousek; M Kerry O'Banion
Journal:  J Neurosci       Date:  2007-08-29       Impact factor: 6.167

6.  Carbonyl stress and NMDA receptor activation contribute to methylglyoxal neurotoxicity.

Authors:  Susana Garcia de Arriba; Ute Krügel; Ralf Regenthal; Zacharie Vissiennon; Esther Verdaguer; Anne Lewerenz; Elvira García-Jordá; Mercé Pallas; Antoni Camins; Gerald Münch; Karen Nieber; Clemens Allgaier
Journal:  Free Radic Biol Med       Date:  2005-11-02       Impact factor: 7.376

Review 7.  Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.

Authors:  Velandai Srikanth; Annette Maczurek; Thanh Phan; Megan Steele; Bernadette Westcott; Damian Juskiw; Gerald Münch
Journal:  Neurobiol Aging       Date:  2009-05-22       Impact factor: 4.673

8.  Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples.

Authors:  Naila Rabbani; Paul J Thornalley
Journal:  Nat Protoc       Date:  2014-07-24       Impact factor: 13.491

9.  Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events.

Authors:  Rachael A McCloy; Samuel Rogers; C Elizabeth Caldon; Thierry Lorca; Anna Castro; Andrew Burgess
Journal:  Cell Cycle       Date:  2014-03-06       Impact factor: 4.534

10.  The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs.

Authors:  Jing Xue; Rashmi Ray; David Singer; David Böhme; David S Burz; Vivek Rai; Ralf Hoffmann; Alexander Shekhtman
Journal:  Biochemistry       Date:  2014-05-13       Impact factor: 3.162

View more
  6 in total

Review 1.  Targeting Inflammatory Pathways in Alzheimer's Disease: A Focus on Natural Products and Phytomedicines.

Authors:  Matthew J Sharman; Giuseppe Verdile; Shanmugam Kirubakaran; Cristina Parenti; Ahilya Singh; Georgina Watt; Tim Karl; Dennis Chang; Chun Guang Li; Gerald Münch
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

Review 2.  The Effects of Modified Curcumin Preparations on Glial Morphology in Aging and Neuroinflammation.

Authors:  Faheem Ullah; Rashmi Gamage; Monokesh K Sen; Erika Gyengesi
Journal:  Neurochem Res       Date:  2022-01-06       Impact factor: 3.996

3.  Suppression of the Peripheral Immune System Limits the Central Immune Response Following Cuprizone-Feeding: Relevance to Modelling Multiple Sclerosis.

Authors:  Monokesh K Sen; Mohammed S M Almuslehi; Erika Gyengesi; Simon J Myers; Peter J Shortland; David A Mahns; Jens R Coorssen
Journal:  Cells       Date:  2019-10-24       Impact factor: 6.600

4.  The cytokines interleukin-6 and interferon-α induce distinct microglia phenotypes.

Authors:  Phillip K West; Andrew N McCorkindale; Boris Guennewig; Thomas M Ashhurst; Barney Viengkhou; Emina Hayashida; So Ri Jung; Oleg Butovsky; Iain L Campbell; Markus J Hofer
Journal:  J Neuroinflammation       Date:  2022-04-16       Impact factor: 9.587

5.  Effects of a solid lipid curcumin particle formulation on chronic activation of microglia and astroglia in the GFAP-IL6 mouse model.

Authors:  Faheem Ullah; Rustam Asgarov; Madhuri Venigalla; Huazheng Liang; Garry Niedermayer; Gerald Münch; Erika Gyengesi
Journal:  Sci Rep       Date:  2020-02-11       Impact factor: 4.379

6.  Evaluation of Phytosomal Curcumin as an Anti-inflammatory Agent for Chronic Glial Activation in the GFAP-IL6 Mouse Model.

Authors:  Faheem Ullah; Huazheng Liang; Garry Niedermayer; Gerald Münch; Erika Gyengesi
Journal:  Front Neurosci       Date:  2020-03-12       Impact factor: 4.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.